CLINUVEL Pharmaceuticals Limited Showcases Global Programs at the 2026 AAD Meeting
CLINUVEL Pharmaceuticals Limited (ASX: CUV) is showcasing its influence at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver. The company's programs for treating vitiligo and erythropoietic protoporphyria (EPP) take center stage, alongside the unveiling of their proprietary Vitiligo Visual Algorithm (VVA), an AI-driven tool designed to objectively assess pigmentation. CLINUVEL’s team is presenting its developments, including the FDA-approved SCENESSE® (afamelanotide) for EPP, and is focused on further advancing treatments for vitiligo.
The company’s Pavilion of Photomedicine has been reimagined for this year’s meeting, offering attendees an immersive experience into CLINUVEL's scientific heritage and future direction. With over 20,000 dermatology professionals expected at the meeting, CLINUVEL is fostering valuable engagement through satellite symposia, where results from their ongoing programs are being discussed. The event represents a significant opportunity for CLINUVEL to receive real-time feedback and strengthen collaborations within the dermatology community.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
CLINUVEL Pharmaceuticals Limited Showcases Global Programs at the 2026 AAD Meeting
CLINUVEL Pharmaceuticals Limited (ASX: CUV) is showcasing its influence at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver. The company's programs for treating vitiligo and erythropoietic protoporphyria (EPP) take center stage, alongside the unveiling of their proprietary Vitiligo Visual Algorithm (VVA), an AI-driven tool designed to objectively assess pigmentation. CLINUVEL’s team is presenting its developments, including the FDA-approved SCENESSE® (afamelanotide) for EPP, and is focused on further advancing treatments for vitiligo.
The company’s Pavilion of Photomedicine has been reimagined for this year’s meeting, offering attendees an immersive experience into CLINUVEL's scientific heritage and future direction. With over 20,000 dermatology professionals expected at the meeting, CLINUVEL is fostering valuable engagement through satellite symposia, where results from their ongoing programs are being discussed. The event represents a significant opportunity for CLINUVEL to receive real-time feedback and strengthen collaborations within the dermatology community.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au